What question did this study set out to answer?

The research aims to assess the incidence of hearing loss among platinum-naïve patients treated with immune checkpoint inhibitors.

March 10, 2026Otolaryngology0 citationsOpen Access

Rate of Hearing Loss in Platinum‐Naïve Patients Receiving Immune Checkpoint Inhibitors

View Full Paper

KBKaitlyn A. BrooksThe University of Texas MD Anderson Cancer Center GGGabriel GidleyThe University of Texas MD Anderson Cancer Center OGOlivia GrimleyThe University of Texas MD Anderson Cancer Center

Key Points

The research aims to assess the incidence of hearing loss among platinum-naïve patients treated with immune checkpoint inhibitors.
Monitored patients receiving immune checkpoint inhibitors
Employed standardized audiologic surveillance
Analyzed criteria for hearing loss
A significant proportion of patients experienced hearing loss
Need for further studies to quantify ICI ototoxicity
Current findings highlight potential risks associated with treatment

Abstract

A significant proportion of our monitored platinum-naïve ICI patients met hearing-loss criteria. Prospective studies with standardized audiologic surveillance are needed to further quantify the true incidence of ICI ototoxicity.

Perguntar à IA

Bookmark

View Full Paper

Perguntar à IA

Bookmark

View Full Paper

Rate of Hearing Loss in Platinum‐Naïve Patients Receiving Immune Checkpoint Inhibitors

Key Points

Abstract

Cite This Study

Also Consider

Also Consider